Please assess the completion status of the following clinical trial:

Trial Title: Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. English-speaking adults~2. Age 18-70~3. Survivor of a variety of traumas (e.g., motor vehicle and accidents, burns and others injuries, combat, World Trade Center attack, etc.)~4. Diagnosed with PTSD~5. In good health. For persons with chronic injuries/conditions related to their accidents, good health is defined as the injury being in a state of stabilization and able to attend weekly outpatient sessions.~Exclusion Criteria:~1. Current organic mental disorder~2. Schizophrenia or symptoms of psychosis/delusions~3. Bipolar disorder~4. Current substance abuse or dependence~5. Active suicidal/homicidal ideation, intent, or plan~6. Use of pacemaker~7. Significant health impairment, including renal disease~8. Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or anti-depressant medication~9. Hypersensitivity to cycloserine~10. History of seizures~11. Pregnant or currently trying to conceive, or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- D-cycloserine (Type: EXPERIMENTAL): 100 mg on days of therapy session
- Placebo (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).